APRESOLINE Drug Patent Profile

When do Apresoline patents expire, and what generic alternatives are available?

Apresoline is a drug marketed by Novartis and is included in two NDAs.

The generic ingredient in APRESOLINE is hydralazine hydrochloride; hydrochlorothiazide. There are two drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide profile page.

Summary for APRESOLINE

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	79
Clinical Trials:	5
DailyMed Link:	APRESOLINE at DailyMed

Recent Clinical Trials for APRESOLINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medical College of Wisconsin	N/A
Vanderbilt University Medical Center	Phase 2
National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2

See all APRESOLINE clinical trials

US Patents and Regulatory Information for APRESOLINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	APRESOLINE	hydralazine hydrochloride	INJECTABLE;INJECTION	008303-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Novartis	APRESOLINE	hydralazine hydrochloride	TABLET;ORAL	008303-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Novartis	APRESOLINE	hydralazine hydrochloride	TABLET;ORAL	008303-004	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Novartis	APRESOLINE	hydralazine hydrochloride	TABLET;ORAL	008303-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Novartis	APRESOLINE-ESIDRIX	hydralazine hydrochloride; hydrochlorothiazide	TABLET;ORAL	012026-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Novartis	APRESOLINE	hydralazine hydrochloride	TABLET;ORAL	008303-005	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Apresoline Market Dynamics and Financial Trajectory: Hydralazine Patent, FDA, Generic and Commercial Analysis

Last updated: August 22, 2026

Apresoline is the historical brand name for hydralazine, an antihypertensive first commercialized in the 1950s. Its commercial trajectory is defined by complete genericization, loss of brand economics, limited current prescribing, and the absence of a meaningful standalone financial disclosure. Hydralazine remains FDA-approved in generic tablets and injectable formulations, but Apresoline is not a current growth brand in the United States. Its value is concentrated in low-cost generic supply, hospital use, and selected clinical niches such as severe hypertension and heart failure combinations.

What is Apresoline and how is hydralazine used?

Apresoline is hydralazine hydrochloride, a direct-acting vasodilator. It lowers blood pressure primarily by relaxing arteriolar smooth muscle. The drug is used for hypertension and, in combination with isosorbide dinitrate, for selected patients with heart failure, particularly when standard renin-angiotensin pathway therapies are unsuitable or in specific patient populations (U.S. Food and Drug Administration [FDA], 2023; DailyMed, 2024).

Apresoline active ingredient and dosage forms

Current hydralazine products generally include:

Product	Common strengths or presentation	Principal use
Hydralazine tablets	10 mg, 25 mg, 50 mg, 100 mg	Chronic hypertension
Hydralazine injection	Commonly 20 mg/mL presentations	Acute or severe hypertension
Hydralazine plus isosorbide dinitrate	Combination tablets sold under other brands	Heart failure in selected patients

The original Apresoline brand is associated with Ciba, later Ciba-Geigy and Novartis. Current U.S. supply is primarily generic rather than branded.

When did Apresoline lose exclusivity?

Apresoline lost meaningful market exclusivity many decades ago. Hydralazine was introduced before the modern Hatch-Waxman framework and has no commercially relevant current New Chemical Entity exclusivity, pediatric exclusivity, or orphan-drug exclusivity.

Exclusivity category	Current Apresoline status
New Chemical Entity exclusivity	Expired
Orphan-drug exclusivity	None identified for hydralazine
Pediatric exclusivity	None currently relevant
Brand-based market protection	Expired
Generic competition	Established for decades
Biosimilar protection	Not applicable

The practical loss of exclusivity occurred when generic hydralazine products entered the market. Because the active ingredient has been available for decades, the market now operates as a mature generic category rather than an originator product market.

What patents protect Apresoline and hydralazine?

No commercially meaningful active patent estate protects Apresoline or conventional hydralazine tablets in the United States. The historical compound and basic oral dosage-form patents expired long ago.

The current IP position can be summarized as follows:

IP category	Apresoline and hydralazine position
Composition-of-matter patents	Historical patents expired
Conventional tablet patents	Historical protection expired
Injection formulation patents	No material current exclusivity identified
Method-of-use patents	No meaningful current blocking estate identified
Combination patents	Separate products, particularly hydralazine-isosorbide dinitrate, may have had distinct historical protection
Orange Book-listed patents	No current Apresoline patent barrier of commercial significance
Regulatory exclusivity	Expired or not applicable

Patent protection for a combination product should not be confused with protection for Apresoline itself. A formulation containing hydralazine and isosorbide dinitrate may have had separate labeling, formulation, or method-of-use rights, but those rights do not restore exclusivity to standalone hydralazine.

How strong is the Apresoline patent estate?

The Apresoline patent estate is commercially weak. It has no evident ability to delay generic entry, support a Paragraph IV litigation strategy, or preserve premium pricing. Any current competitive advantage would have to come from manufacturing reliability, supply contracts, injectable capacity, distribution, or regulatory execution rather than patents.

What is the FDA regulatory status of Apresoline?

The FDA regulatory status differs between the historical brand and generic hydralazine.

Brand status

Apresoline is not a current U.S. growth product with an active originator commercial platform. Historical branded labeling and legacy product records may remain in FDA databases, but the active market is supplied primarily through abbreviated new drug applications and generic prescription products.

Generic status

Hydralazine tablets and injections remain approved generic products. Generic manufacturers can enter under the abbreviated new drug application pathway by demonstrating pharmaceutical equivalence and bioequivalence to the relevant reference product, subject to product-specific FDA requirements (FDA, 2024a).

Orange Book status

The Orange Book remains relevant for approved hydralazine reference products and generic-equivalence determinations. It does not create an active exclusivity moat for Apresoline. The absence of a meaningful listed patent barrier means a qualifying generic applicant generally does not face an originator patent stay tied to Apresoline.

Which companies are challenging Apresoline through Paragraph IV filings?

No material current Paragraph IV challenge to Apresoline is evident because Apresoline does not have a commercially significant active patent estate. Paragraph IV litigation is generally used against listed patents protecting an innovator product. That mechanism has little relevance to a legacy drug whose principal composition and dosage-form rights expired decades ago.

Current competition is more likely to involve:

• ANDA approvals for hydralazine tablets
• Manufacturer exits and reentries
• Drug-shortage responses
• Hospital purchasing contracts
• Price competition among generic suppliers
• Manufacturing and quality compliance

The principal commercial risk is supply interruption rather than patent litigation.

What generic entry risks exist for Apresoline?

Generic entry risk is structurally complete. The relevant issue is not whether generics can enter, but how many suppliers remain active and whether they can maintain supply.

Generic market structure

Hydralazine is exposed to the standard economics of mature generic drugs:

1. Multiple approved suppliers reduce pricing power.
2. Low unit prices limit the incentive to invest in redundant manufacturing capacity.
3. Hospital and wholesaler buyers can shift volume between suppliers.
4. Manufacturing deviations or raw-material shortages can affect availability.
5. Injectable supply is more operationally constrained than tablet supply.

Tablet hydralazine is generally easier to manufacture and distribute. Injectable hydralazine has greater exposure to sterile manufacturing capacity, quality systems, fill-finish availability, and hospital procurement requirements.

What formulations are protected by Apresoline-related intellectual property?

Conventional hydralazine tablets have no meaningful current formulation exclusivity. The historical Apresoline franchise did not retain a protected extended-release or proprietary delivery platform comparable to modern lifecycle-management products.

Potentially differentiated categories include:

Formulation or use	Commercial/IP relevance
Immediate-release tablets	Mature generic market
Injectable hydralazine	Hospital and acute-care supply; operational barriers exceed patent barriers
Hydralazine-isosorbide dinitrate combinations	Separate branded and generic competitive category
Modified-release hydralazine	Limited current commercial significance
Compounded formulations	Pharmacy-specific, not an Apresoline exclusivity strategy

A company seeking to create new value around hydralazine would likely need a new delivery system, combination product, dosing technology, or clinical positioning. Any such strategy would require new patents and regulatory support; it would not rely on the legacy Apresoline brand.

What patent litigation affects Apresoline?

No significant current Apresoline patent litigation is associated with the mature standalone hydralazine market. The product’s legal exposure is mainly regulatory and commercial.

Relevant dispute categories could include:

• ANDA approval or labeling disputes
• Product liability claims
• Manufacturing quality claims
• Trademark or trade-name disputes
• Contract disputes involving generic supply
• Competition among suppliers during shortages

These matters differ from an originator patent case. They are unlikely to produce a durable exclusivity period or materially change the long-term market structure.

Are there biosimilar risks for Apresoline?

Biosimilar risk is not applicable. Hydralazine is a small-molecule chemical drug, not a biologic. Competitive substitution occurs through generic drug regulation, not the biosimilar pathway under the Public Health Service Act.

The relevant substitutes are:

• Other generic hydralazine products
• Other direct vasodilators
• Calcium-channel blockers
• Beta blockers
• ACE inhibitors and ARBs
• Mineralocorticoid receptor antagonists
• Hydralazine-isosorbide dinitrate combination products

Clinical substitution is constrained by indication, tolerability, dosing frequency, renal function, pregnancy considerations, and physician preference. Hydralazine remains a niche therapy rather than a first-line broad hypertension product.

How does Apresoline compare with competing antihypertensive drugs?

Hydralazine has a weaker commercial position than newer and more routinely prescribed antihypertensive classes.

Drug class	Relative market position	Competitive effect on hydralazine
ACE inhibitors and ARBs	Broad first-line use	Strong substitution pressure
Calcium-channel blockers	Broad first-line use	Strong substitution pressure
Thiazide diuretics	Low-cost, established use	Strong price and clinical competition
Beta blockers	Used in selected cardiovascular settings	Moderate competition
Minoxidil	Niche direct vasodilator	Limited direct competition
Hydralazine	Selected resistant, acute, pregnancy-related, and heart-failure uses	Defensive niche position

Hydralazine’s limitations include frequent dosing, reflex tachycardia, fluid retention, variable blood-pressure response, and drug-induced lupus risk. These characteristics reduce its use in routine hypertension and support continued generic price compression.

What is the financial trajectory of Apresoline?

No reliable standalone revenue series for Apresoline is publicly disclosed by its historical owner or current generic manufacturers. Novartis does not report Apresoline revenue as a separately material product line in its current financial disclosures. The commercial trajectory can therefore be assessed through market structure rather than brand sales.

Financial timeline

Period	Commercial position	Financial implication
1950s to 1970s	Originator antihypertensive	Brand pricing and physician adoption
1980s to 1990s	Generic competition expands	Declining brand share and pricing pressure
2000s	Mature generic product	Low growth, fragmented supply
2010s	Continued generic use, selected hospital demand	Limited revenue scale; occasional shortage-driven volatility
2020s	Legacy generic and injectable niche	Stable clinical demand, low margin, supply-chain sensitivity

Revenue exposure for a generic manufacturer depends on volume, dosage form, contract status, and supply availability. A supplier with a temporary shortage advantage may experience short-term price improvement. That effect is usually unstable and does not represent durable brand value.

What licensing deals involve Apresoline?

No major current licensing transaction is publicly associated with Apresoline as a standalone commercial asset. The historical product passed through corporate ownership involving Ciba and Ciba-Geigy before the Novartis structure. Those legacy corporate transactions do not represent an active licensing opportunity in the present market.

The more commercially relevant licensing opportunities would involve:

• Hydralazine combination therapies
• Hospital injectable supply agreements
• Novel controlled-release formulations
• Fixed-dose products
• Geographic commercialization rights
• Contract manufacturing and authorized-generic arrangements

A license centered only on legacy Apresoline branding would have limited strategic value unless paired with distribution rights, a differentiated formulation, or an established institutional customer base.

What geographic markets still use Apresoline?

Hydralazine has international availability under multiple brand and generic names. The exact commercial status of Apresoline varies by jurisdiction because national registration, brand ownership, and reimbursement differ.

The United States is predominantly a generic market. Other countries may retain legacy hydralazine trademarks or local brand presentations, but the underlying product remains mature and generally off-patent. Geographic value is therefore linked to:

• Local regulatory registration
• Hospital procurement
• National reimbursement
• Local manufacturing
• Import reliability
• Brand recognition in specialist markets

There is no global patent-based exclusivity story for Apresoline.

What manufacturing and IP barriers affect hydralazine?

Manufacturing barriers are more important than intellectual property barriers.

Tablets

Tablet production is relatively accessible for established generic manufacturers. Key risks include active pharmaceutical ingredient sourcing, quality control, packaging, and supply forecasting.

Injection

Injectable hydralazine carries higher operational requirements. Suppliers must maintain sterile manufacturing, validated processes, container-closure integrity, and compliance with FDA current good manufacturing practice requirements. These constraints can reduce the number of reliable suppliers even when patents do not restrict entry.

Active pharmaceutical ingredient

Hydralazine API sourcing can affect margin and continuity. A limited number of qualified API suppliers, changes in international manufacturing, or regulatory action against a production site can create temporary market tightness.

Key Takeaways

• Apresoline is the legacy brand for hydralazine hydrochloride.
• The product has lost all meaningful originator exclusivity.
• Standalone hydralazine is primarily a mature generic market.
• No material current patent estate protects conventional Apresoline tablets.
• Paragraph IV litigation and biosimilar competition are not central risks.
• FDA-approved hydralazine tablets and injections remain commercially available through generic pathways.
• Injectable supply has greater manufacturing and shortage risk than oral tablets.
• No standalone Apresoline revenue trajectory is publicly disclosed.
• Financial value is concentrated in low-cost generic volume, institutional contracts, and supply reliability.
• Any future product differentiation would require a new formulation, combination product, or delivery platform.

FAQs About Apresoline Market and Patent Status

Does Apresoline still have brand value?

Limited brand value remains in historical recognition and physician familiarity. Current economic value is primarily associated with hydralazine supply rather than the Apresoline trademark.

Is hydralazine still profitable for pharmaceutical manufacturers?

Hydralazine can generate revenue for generic suppliers, but profitability is usually volume-driven and constrained by low prices. Injectable products may provide better commercial value when supply is limited, although manufacturing costs and compliance requirements are higher.

Can a company launch a generic version of Apresoline without patent litigation?

Generally, yes, provided the product meets FDA requirements and no applicable listed patent or regulatory exclusivity blocks approval. The legacy Apresoline franchise does not present a material modern patent barrier.

Is Apresoline used for heart failure?

Hydralazine may be used with isosorbide dinitrate in selected heart-failure patients. The combination indication should be analyzed separately from standalone Apresoline because its labeling, clinical evidence, and commercial products differ.

What is the main investment risk in the hydralazine market?

The main risks are limited market growth, low generic pricing, supplier concentration, manufacturing disruption, and declining routine use relative to first-line antihypertensive therapies. Patent expiry is no longer the relevant risk because exclusivity ended long ago.

References

1. DailyMed. (2024). Hydralazine hydrochloride tablet and injection prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2023). Hydralazine hydrochloride prescribing information. FDA.
3. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
4. U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs database. FDA.
5. Novartis AG. (2024). Annual report 2023. Novartis.